{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:06Z","timestamp":1793214606028,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ajo.2015.12.032","type":"journal-article","created":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T21:03:22Z","timestamp":1451941402000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Rituximab in the Treatment of Refractory Noninfectious Scleritis"],"prefix":"10.1016","volume":"164","author":[{"given":"Jennifer H.","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merih","family":"Oray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2659-7450","authenticated-orcid":false,"given":"Lidia","family":"Cocho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ajo.2015.12.032_bib1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajo.2009.07.021","article-title":"Scleritis and systemic disease association in a community-based referral practice","volume":"148","author":"Raiji","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2015.12.032_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","article-title":"Clinical characteristics of a large cohort of patients with scleritis and episcleritis","volume":"119","author":"Sainz de la Maza","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2015.12.032_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/ICO.0000000000000437","article-title":"Ocular inflammation in the setting of concomitant systemic autoimmune conditions in an older male population","volume":"34","author":"Levitt","year":"2015","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.ajo.2015.12.032_bib4","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2015.12.032_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ophtha.2003.06.006","article-title":"Evaluation of patients with scleritis for systemic disease","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2015.12.032_bib6","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0161-6420(84)34160-4","article-title":"Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression","volume":"91","author":"Foster","year":"1984","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2015.12.032_bib7","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2015.12.032_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2015.12.032_bib9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","article-title":"Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis","volume":"32","author":"Heiligenhaus","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ajo.2015.12.032_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000336188","article-title":"Rituximab for noninfectious uveitis","volume":"51","author":"Miserocchi","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2015.12.032_bib11","first-page":"309","article-title":"Biologic agents in inflammatory eye disease","volume":"6","author":"Posarelli","year":"2011","journal-title":"J Ophthalmic Vis Res"},{"issue":"6","key":"10.1016\/j.ajo.2015.12.032_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ophtha.2015.01.016","article-title":"Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease","volume":"122","author":"Joshi","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2015.12.032_bib13","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/ard.2004.027128","article-title":"Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab","volume":"64","author":"Ahmadi-Simab","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ajo.2015.12.032_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/09273940802331643","article-title":"Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis","volume":"16","author":"Onal","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"10.1016\/j.ajo.2015.12.032_bib15","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/bjo.2005.075689","article-title":"Successful treatment of Wegener's granulomatosis associated scleritis with rituximab","volume":"89","author":"Cheung","year":"2005","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2015.12.032_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/09273948.2013.788724","article-title":"Rituximab therapy for refractory idiopathic scleritis","volume":"21","author":"Bogdanic-Werner","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajo.2015.12.032_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2015.12.032_bib18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1442-9071.1991.tb00663.x","article-title":"Prediction of response to treatment in patients with scleritis using a standardised scoring system","volume":"19","author":"McCluskey","year":"1991","journal-title":"Aust N Z J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2015.12.032_bib19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2013.772982","article-title":"Pharmacotherapy of scleritis: current paradigms and future directions","volume":"14","author":"Beardsley","year":"2013","journal-title":"Expert Opin Pharmacother"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415300532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939415300532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:31:01Z","timestamp":1757597461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939415300532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":19,"alternative-id":["S0002939415300532"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2015.12.032","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in the Treatment of Refractory Noninfectious Scleritis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2015.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}